Table 5.
Association between G2I classes and clinico-pathological parameters
| Clinicopathological Parameters | Total n = 135 (%) | G2I-1 19 | G2I-2 88 | G2I-3 28 | χ2test p-value |
|---|---|---|---|---|---|
| Lymph node involvement | |||||
| pN0 |
75 (56) |
12 (63) |
43 (49) |
20 (83) |
0.086 |
| pN+ |
60 (44) |
7 (37) |
45 (51) |
8 (29) |
|
| Age (years) | |||||
| <=55 |
70 (52) |
8 (42) |
51 (58) |
11 (39) |
0.149 |
| >55 |
65 (48) |
11 (58) |
37 (42) |
17 (61) |
|
| Histological size (mm) | |||||
| <= 20 |
90 (67) |
16 (84) |
57 (65) |
17 (61) |
0.2 |
| > 20 |
45 (33) |
3 (16) |
31 (35) |
11 (39) |
|
| Scarff Bloom Richardson (SBR) Grade | |||||
| 1 |
25 (18) |
6 (32) |
15 (17) |
4 (14) |
0.037 |
| 2 |
71 (53) |
12 (63) |
48 (55) |
11 (39) |
|
| 3 |
39 (29) |
1 ( 5) |
25 (28) |
13 (39) |
|
| Steroid Hormone Receptor status | |||||
| HR+ : > = 10% |
116 (86) |
18 (95) |
74 (84) |
24 (86) |
0.48 |
| HR- |
19 (14) |
1 ( 5) |
14 (16) |
4 (14) |
|
| Nottingham prognostic index (NPI) | |||||
| 1 + 2 |
30 (22) |
6 (32) |
20 (23) |
4 (14) |
0.37 |
| 3 |
85 (63) |
13 (68) |
50 (57) |
22 (79) |
|
| 4 |
20 (15) |
0 ( 0) |
18 (20) |
2 ( 7) |
|
| Mib1 | |||||
| <20% |
93 (69) |
18 (95) |
60 (68) |
15 (54) |
0.011 |
| ≥20% |
42 (31) |
1 ( 5) |
28 (32) |
13 (46) |
|
| Ihc intrinsic classification(a) | |||||
| LA |
83 (62) |
16 (84) |
55 (64) |
12 (43) |
0.014 |
| LB + her2+ Basal |
50 (38) |
3 (16) |
31 (36) |
16 (57) |
|
| unclassified |
2 |
0 |
2 |
0 |
|
| p53 status (b) | |||||
| - |
95 (71) |
19 (100) |
64 (73) |
13 (46) |
0.0003 |
| + |
39 (29) |
0 ( 0) |
24 (27) |
15 (54) |
|
| At least one amplicon | |||||
| No |
71 (53) |
16 (84) |
47 (53) |
8 (29) |
0.001 |
| Yes | 64 (47) | 3 (16) | 41 (47) | 20 (71) | |
(a) immunohistochemistry based on intrinsic classification, LA: luminal A, LB: luminal B, Her2: Her2-enriched; (b) TP53 mutation or immunohistochemical detection of p53 accumulation.